Circulating tumour DNA technology: the future of cancer management?

Cancer incidence is increasing worldwide and in the UK it is estimated that 1 in 2 people born after 1960 will be diagnosed with some form of cancer in their lifetime. Could circulating tumour (ct) DNA technology help the health system meet the challenge of this cancer burden, and what needs to be done to maximise its utility?